Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals
Top Cited Papers
Open Access
- 10 September 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (9), e44454
- https://doi.org/10.1371/journal.pone.0044454
Abstract
The SMART study was a trial of intermittent use of antiretroviral therapy (ART) (drug conservation [DC]) versus continuous use of ART (viral suppression [VS]) as a strategy to reduce toxicities, including cardiovascular disease (CVD) risk. We studied the predictive value of high sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6) and D-dimer with CVD morbidity and mortality in HIV-infected patients who were enrolled in SMART beyond other measured CVD risk factors. A blood sample was available in 5098 participants who were enrolled in the SMART study for the measurement of IL-6, hsCRP and D-dimer. Hazard ratios (HR) with 95% CI for CVD events were estimated for each quartile (Q) for each biomarker vs the 1st quartile and for 1 SD higher levels. For both treatment groups combined, unadjusted and adjusted HRs were determined using Cox regression models. There were 252 participants who had a CVD event over a median follow-up of 29 months. Adjusted HRs (95% CI) for CVD for Q4 vs Q1 were 4.65 (2.61, 8.29), 2.10 (1.40, 3.16), and 2.14 (1.38, 3.33) for IL-6, hsCRP and D-dimer, respectively. Associations were similar for the DC and VS treatment groups (interaction p-values were >0.30). The addition of the three biomarkers to a model that included baseline covariates significantly improved model fit (p<0.001). Area under the curve (AUC) estimates improved with inclusion of the three biomarkers in a model that included baseline covariates corresponding to other CVD risk factors and HIV factors (0.741 to 0.771; p<0.001 for difference). In HIV-infected individuals, IL-6, hsCRP and D-dimer are associated with an increased risk of CVD independent of other CVD risk factors. Further research is needed to determine whether these biomarkers can be used to improve CVD risk prediction among HIV positive individuals.Keywords
This publication has 38 references indexed in Scilit:
- Cardiovascular disease in HIV infectionCurrent Opinion in HIV and AIDS, 2011
- Cardiovascular implications from untreated human immunodeficiency virus infectionEuropean Heart Journal, 2011
- Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Prevalence and prognostic significance of ECG abnormalities in HIV–infected patients: results from the Strategies for Management of Antiretroviral Therapy studyJournal of Electrocardiology, 2010
- Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV InfectionThe Journal of Infectious Diseases, 2010
- C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysisThe Lancet, 2009
- Activation and Coagulation Biomarkers Are Independent Predictors of the Development of Opportunistic Disease in Patients with HIV InfectionThe Journal of Infectious Diseases, 2009
- Associations of factor VIIIc, D‐dimer, and plasmin–antiplasmin with incident cardiovascular disease and all‐cause mortalityAmerican Journal of Hematology, 2009
- Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaborationThe Lancet, 2008
- Estimation of time‐dependent area under the ROC curve for long‐term risk predictionStatistics in Medicine, 2005